Sign Up Today and Learn More About Magenta Therapeutics Stock
Invest in or calculate the value of your shares in Magenta Therapeutics or other pre-IPO companies through EquityZen's platform.
Magenta Therapeutics Stock
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
About Magenta Therapeutics Stock
Founded
2016
Headquarters
Cambridge, MA, US
Total Funding
151M
Industries
Science and Engineering, Health Care, Biotechnology
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Magenta Therapeutics Press Mentions
Stay in the know about the latest news on Magenta Therapeutics
Magenta Therapeutics Announces Closing of Initial Public Offering
Business Wire (press release) • Jun 25, 2018
Magenta Therapeutics (NASDAQ:MGTA) to Raise $100 Million in IPO
StockNewsTimes • Jun 24, 2018
Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
• Apr 06, 2018
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
• Mar 07, 2018
Magenta Therapeutics Management
Leadership team at Magenta Therapeutics
CSO
Michael Cooke
VP and Head of Business Development
Christina Isacson
Join now and verify your accreditation status to gain access to:
- Magenta Therapeutics Current Valuation
- Magenta Therapeutics Stock Price
- Magenta Therapeutics Management
- Available deals in Magenta Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Magenta Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Magenta Therapeutics Revenue and Financials
- Magenta Therapeutics Highlights
- Magenta Therapeutics Business Model
- Magenta Therapeutics Risk Factors
- Magenta Therapeutics Research Report from SACRA Research
Trading Magenta Therapeutics Stock
How to invest in Magenta Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Magenta Therapeutics through EquityZen funds. These investments are made available by existing Magenta Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Magenta Therapeutics stock?
Shareholders can sell their Magenta Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."